Off Script: A Pharma Manufacturing Podcast

FDA backs Lilly Alzheimer’s drug; Pfizer Duchenne gene therapy fails; Talc plaintiffs seek J&J bankruptcy restraining order [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good — FDA AdComm backs Eli Lilly Alzheimer’s drug
The bad — Pfizer gene therapy fails phase 3 Duchenne trial
The ugly — Talc plaintiffs seek restraining order on J&J bankruptcy tactic

AZ's Tagrisso shines in phase 3 trial, BMS layoffs, FDA violations at Jiangsu Hengrui site [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good —  AstraZeneca’s Tagrisso delivers 84% progression-free survival in trial
The bad — BMS to let go of 863 employees at NJ site 
The ugly — FDA inspection uncovers multiple violations at Jiangsu Hengrui Pharmaceuticals site

J&J depression drug aces trial, Takeda plans layoffs, FDA delays review of Sanofi-Regeneron's Dupixent [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good — J&J depression drug aces late-stage trial
The bad — Takeda plans layoffs at Massachusetts sites
The ugly —  FDA delays review of Sanofi-Regeneron's Dupixent in COPD

Mining pharma's reshoring rush

When the pandemic hit and Americans found themselves looking to China for critical medical supplies, the idea of reshoring — a concept that had drifted along the currents of the manufacturing sector for over a decade — embedded itself into pharma discourse with renewed luster.

During this podcast, Chief Content Director Karen Langhauser will share a summary of our most recent cover story, Mining pharma's reshoring rush, and discuss where the industry stands amid the U.S. movement to bring the manufacturing of generic drugs, APIs and ingredients home.

 

FDA approves biosim to Regeneron Eylea, Evotec exits gene therapy, J&J reports deaths in radioligand trial [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good —  FDA approves first interchangeable biosims to Regeneron Eylea 
The bad — Evotec exits gene therapy
The ugly —  J&J reports deaths in early-stage radioligand trial

FDA approves Amgen's T-cell engager for lung cancer, BioMarin announces layoffs, FDA delays Ascendis drug review [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good —  FDA approves Amgen T-cell engager for small cell lung cancer 
The bad — BioMarin announces 170 layoffs 
The ugly — FDA delays review of Ascendis hypoparathyroidism drug

Vertex submits NDA for CF drug, MacroGenics reports ADC prostate cancer trial patient deaths, FTC extends review of Novo-Catalent deal [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good —  Vertex submits NDA for CF drug
The bad — MacroGenics reports patient deaths in prostate cancer ADC trial 
The ugly — FTC extends review of Novo-Catalent deal

Neurocrine wins FDA nod for 'sprinkle' Ingrezza, Moderna-Metagenomi deal ends, Emergent's layoffs [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good — Neurocrine wins FDA nod for 'sprinkle' Ingrezza formulation 
The bad — Moderna, Metagenomi end gene editing collab
The ugly — Emergent announces layoffs, closes sites 

Novartis wins rare cancer pediatric indication, BMS layoffs, McKinsey under fire [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — Novartis wins rare cancer pediatric indication for Lutathera
The bad — BMS unveils cost-saving initiative, layoffs
The ugly — McKinsey under fire for alleged role in opioid crisis  

GSK antibiotic hits phase 3 goals, Genentech-Adaptimmune collab ends, Par Pharma recall [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — GSK antibiotic hits phase 3 goals in gonorrhea
The bad — Genentech ends $3B Adaptimmune T-cell collab
The ugly — Par Pharmaceutical recalls Treprostinil injection for potential contamination